News at a glance.

Galenica continues to grow in the 2023 financial year

Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 12 March 2024

The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.0 million. Adjusted for the extraordinary sales related to COVID-19 (self-tests, COVID-19 vaccinations and rapid tests) in the prior-year period, growth amounted to a substantial 5.0%. 

Adjusted¹ EBIT increased by 0.4% to CHF 191.3 million, despite special factors in the amount of CHF 9.8 million. Without these special factors, adjusted¹ EBIT would have increased by 5.5% to CHF 201.1 million. Thanks to this solid result, the Board of Directors will propose to the Annual General Meeting a dividend at the previous year’s level (CHF 2.20 per share). 

Outlook for 2024

Galenica expects sales growth of between 3% and 5% for the 2024 financial year. Galenica expects adjusted¹ EBIT to increase by between 8% and 11%. Adjusted for the special factors in the 2023 financial year in the amount of CHF 9.8 million, this results in a stable development of the adjusted¹ EBIT margin (ROS) at 5.4%. Galenica strives for strong yet sustainable dividend growth and plans a dividend for 2024 at least at the previous year’s level.

Detailed information in the Annual report 2023: 

• Key figures for the Galenica Group
• Products & Care segment key figures
• Logistics & IT segment key figures

• read more
• Annual results of the Galenica Group 2023